Prevents bronchospasm. ANDA 203653, held by Ritedose Corp. Levalbuterol Hydrochloride.
As of Nov 16, 2026, ANDA 203653 (Levalbuterol Hydrochloride), held by Ritedose Corp, was first approved by FDA on Mar 22, 2016, with 2 approved supplements and 0 published complete response letters.
Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol Inhalation Solution, USP is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 22, 2016 | Original application | Approved | None posted |
| Levalbuterol HydrochlorideEQ 0.0103% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Levalbuterol HydrochlorideEQ 0.021% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Levalbuterol HydrochlorideEQ 0.042% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Mar 8, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 8, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 22, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters